Biocept, Inc.
BIOC · NASDAQ
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Revenue | $589 | $673 | -$10,285 | $5,587 |
| % Growth | -12.5% | 106.5% | -284.1% | – |
| Cost of Goods Sold | $2,550 | $3,028 | $4,307 | $5,776 |
| Gross Profit | -$1,961 | -$2,355 | -$14,592 | -$189 |
| % Margin | -332.9% | -349.9% | 141.9% | -3.4% |
| R&D Expenses | $409 | $1,040 | $1,216 | $1,366 |
| G&A Expenses | $3,494 | $2,988 | $1,960 | $3,047 |
| SG&A Expenses | $3,744 | $3,703 | $2,795 | $4,022 |
| Sales & Mktg Exp. | $250 | $715 | $835 | $975 |
| Other Operating Expenses | $0 | $0 | $3 | $0 |
| Operating Expenses | $4,153 | $4,743 | $4,011 | $5,388 |
| Operating Income | -$6,114 | -$7,098 | -$18,603 | -$5,577 |
| % Margin | -1,038% | -1,054.7% | 180.9% | -99.8% |
| Other Income/Exp. Net | $2,483 | -$46 | -$45 | $32 |
| Pre-Tax Income | -$3,631 | -$7,144 | -$18,647 | -$5,545 |
| Tax Expense | $0 | $92 | -$125 | -$32 |
| Net Income | -$3,631 | -$7,236 | -$18,522 | -$5,513 |
| % Margin | -616.5% | -1,075.2% | 180.1% | -98.7% |
| EPS | -3,503.04 | -12.46 | -32.58 | -9.8 |
| % Growth | -28,014.3% | 61.8% | -232.4% | – |
| EPS Diluted | -3,503.04 | -12.32 | -32.57 | -9.73 |
| Weighted Avg Shares Out | 1 | 581 | 569 | 563 |
| Weighted Avg Shares Out Dil | 1 | 587 | 569 | 567 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $50 | $46 | $47 | $52 |
| Depreciation & Amortization | $370 | $614 | $441 | $491 |
| EBITDA | -$3,211 | -$6,484 | -$18,162 | -$5,086 |
| % Margin | -545.2% | -963.4% | 176.6% | -91% |